Eli Lilly is acquiring 4E Therapeutics, a company developing non-opioid treatments for pain, in its latest move to expand its drug pipeline through dealmaking.
According to BioPharma Dive, the acquisition is the newest in a series of purchases by Lilly, which has poured more than $18 billion into acquisitions over the past few years.
4E Therapeutics represents a bet on a corner of medicine that has attracted growing interest: finding ways to treat pain that don't rely on opioids. Opioid-based painkillers, while effective, carry serious risks of addiction and dependence — a crisis that has cost hundreds of thousands of American lives over the past two decades. Non-opioid alternatives that work as well without those risks have long been considered something of a holy grail in pharmacology.
For Lilly, the deal fits a broader pattern of aggressive expansion. The company has been one of the pharmaceutical industry's most active dealmakers in recent years, using its financial strength — bolstered in large part by blockbuster sales of its diabetes and weight-loss drugs — to bring in new science from smaller biotechs.
The terms of the 4E deal were not disclosed in the report.
If successful, a non-opioid pain drug from Lilly's pipeline could reach millions of patients who currently have few good options for managing chronic or acute pain safely — making this a deal with implications far beyond Wall Street.